Opinion|Videos|March 28, 2025
Challenges and Emerging Solutions in Treatment for Age Groups: Addressing Disease Control, Safety, and Usability
Author(s)Lisa Swanson, MD, FAAD
Lisa Swanson, MD, FAAD, discusses how current treatment options for this age group fall short in terms of disease control, safety, and ease of use, while highlighting emerging options that promise better efficacy, fewer side effects, and greater convenience.
Advertisement
This news content has been independently developed and is not endorsed by the American Academy of Dermatology.
Video content above is prompted by the following:
- How do current treatment options for this age group fall short in terms of disease control, safety, or ease of use, and what emerging options exist?
Advertisement
Related to this article
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
2
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
3
GLP-1 Candidacy and Prescribing Considerations in Psoriasis
4
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
5